Top Tier Pharmaceutical Companiese are extremely active in the orphan drug space:
- 40% of acquired biotechs between 2008-2012 had an orphan drug in development
- Novartis, GSK, Roche and Pfizer are largest orphan drug companies
- Pfizer, Gilead, Roche, Shire, BMY and Celgene are leading orphan drug acquirer
- 50% of top 20 orphan drugs were either acquired or in-licensed by Top Tier Pharmaceutical Companies
Key Market Statistics:
- Worldwide orphan drug sales forecast to grow to $178 billion by 2020 with a CAGR of +11.7% (2015 to 2020); almost double overall prescription market growth
- Orphan drugs set to be 20% of worldwide prescription sales by 2020 (excluding generics)